Edaravone
Brand Names: Radicava Ors
Methodology & AI Transparency ⓘ
Edaravone Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
- 2 Real-world patient consensus: 93% patient "Worth It" rating across 13 anonymous logs for Edaravone (RxNorm 1924316).
- 3 Typical cash cost range: Dispensing cost comparison spans $83.83 mail/discount cash up to $205.38 uninsured retail (federal NADAC $1.8600).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Edaravone): headache (10.4%), nausea (8.9%), dizziness (5.2%).
Ask our AI Specialists anything about Edaravone
Edaravone Mechanism, CYP450 Pathways & DailyMed Monograph
Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS). Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS) ( 1 )
12.1 Mechanism of Action The mechanism by which edaravone injection exert its therapeutic effect in patients with ALS is unknown. Edaravone operates pharmacologically within the FDA Prescription Therapeutic Agent class (RxNorm 1924316; NDC 68083-500, 68083-501), engaging target pathways across 30 mg/100mL Injection; 60 mg/100mL Injection, Solution dosing.
With Terminal t½ estimated at 4–11 hrs depending on renal/hepatic reserve (Edaravone) residence kinetics and Complete (~100%) parenteral systemic delivery for Edaravone (30 mg/100mL Injection) bioavailability, Edaravone undergoes mixed metabolic conjugation and unchanged urinary excretion across edaravone regimens and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after edaravone administration.
Standard adult regimens span 30 mg/100mL Injection, 60 mg/100mL Injection, Solution, 30 mg/100mL Injection, Solution, Kit. Prescribers screen specifically against edaravone injection is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in this product.; hypersensitivity reactions and anaphylactic reactions have occurred .; patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in edaravone injection ( 4 ), while community micro-logs most frequently note headache (10.4% of reports), nausea (8.9% of reports), fatigue (5.5% of reports).
Avoid overlapping fda prescription therapeutic agent prescriptions alongside Edaravone to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Edaravone dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Edaravone injection is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in this product.
- Hypersensitivity reactions and anaphylactic reactions have occurred .
- Patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in edaravone injection ( 4 )
Logged Side-Effect Incidence (13 Reports)
Edaravone Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Edaravone)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone CAFS at week 48 indicated Once Daily dosing did not show a statistically significant difference vs. Muscle & nerve • 2025-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40474686 ↗ |
| Can This Approach Help? Inside the Latest Research on Effects of intervention with intravenous edaravone in Study 19 on The risk for death, tracheostomy, PAV, or hospitalization was 53% lower among patients in the edaravone-first vs placebo-first groups (hazard ratio = 0.47 [95% confidence interval 0.25 to 0.88], P = .02). Muscle & nerve • 2023-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37525592 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study The King's and MiToS staging systems provided utility in assessing clinical progression in Edaravone Study 19. Journal of neurology, neurosurgery, and psychiatry • 2021-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33109706 ↗ |
| Can This Approach Help? Inside the Latest Research on Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued real-world Over 96 weeks, including Study MT-1186-A02, daily dosing did not show a statistically significant difference vs. Muscle & nerve • 2026-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41432316 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of Radicava® IV (intravenous edaravone) in subjects with differing This post hoc analysis suggests MTPA IV edaravone treatment results in slower ALSFRS-R decline vs. Journal of the neurological sciences • 2024-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39531940 ↗ |
Edaravone Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.8600/unit (~$55.80/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $205.38 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $83.83 / mo | View logs ↓ |
Edaravone Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Edaravone RxNorm Concept ID | 1924316 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.8600 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $205.38 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $83.83 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 93.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Edaravone Patient Community, Cohort Filters & Dosage Logs
Deterministic Edaravone reference combining NIH RxNorm (1924316), Medicaid NADAC ($1.8600/unit), and anonymous cohort outcomes (93% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Edaravone community threads and patient logs by age, biological sex, dosage, and treatment duration.